Table 3.
Treatment-related adverse events occurring in ≥10 % of overall patient population
| Adverse event (n %) | Paz400/Gem1000 (n = 6) | Paz800/Gem1000 (n = 3) | Paz800/Gem1250 (n = 13) | Total (N = 22) |
|---|---|---|---|---|
| Fatigue | 4 (67) | 3 (100) | 8 (62) | 15 (68) |
| Neutropenia | 4 (67) | 1 (33) | 8 (62) | 13 (59) |
| Nausea | 4 (67) | 2 (67) | 6 (46) | 12 (55) |
| Decreased appetite | 2 (33) | 1 (33) | 8 (62) | 11 (50) |
| Leukopenia | 2 (33) | 1 (33) | 7 (54) | 10 (45) |
| Thrombocytopenia | 3 (50) | 1 (33) | 5 (38) | 9 (41) |
| Diarrhea | 3 (50) | 1 (33) | 4 (31) | 8 (36) |
| Vomiting | 1 (17) | 1 (33) | 4 (31) | 6 (27) |
| ALT increased | 1 (17) | 2 (67) | 3 (23) | 6 (27) |
| Dysgeusia | 2 (33) | 3 (100) | 1 (8) | 6 (27) |
| Stomatitis | 4 (67) | 1 (33) | 0 | 5 (23) |
| Alopecia | 0 | 0 | 4 (31) | 4 (18) |
| Hair color changes | 1 (17) | 0 | 3 (23) | 4 (18) |
| AST increased | 1 (17) | 1 (33) | 2 (15) | 4 (18) |
| Epistaxis | 0 | 1 (33) | 3 (23) | 4 (18) |
| Dry skin | 1 (17) | 1 (33) | 1 (8) | 3 (14) |
ALT alanine aminotransferase, AST aspartate aminotransferase, Gem gemcitabine, Paz pazopanib